A Nomogram for Preoperative Prediction of the Risk of Lymph Node Metastasis in Patients with Epithelial Ovarian Cancer
暂无分享,去创建一个
[1] Li Zhang,et al. Predictive value of indicator of CA125 combined with D-dimer (ICD) for lymph node metastasis in patients with ovarian cancer: A two center cohort study , 2022, Journal of Cancer.
[2] R. Rouzier,et al. Using a new diagnostic tool to predict lymph node metastasis in advanced epithelial ovarian cancer leads to simple lymphadenectomy decision rules: A multicentre study from the FRANCOGYN group , 2021, PloS one.
[3] R. Rouzier,et al. Preoperative CT or PET/CT to Assess Pelvic and Para-Aortic Lymph Node Status in Epithelial Ovarian Cancer? A Systematic Review and Meta-Analysis , 2021, Diagnostics.
[4] F. Zhao,et al. The Development and Validation of a CT-Based Radiomics Nomogram to Preoperatively Predict Lymph Node Metastasis in High-Grade Serous Ovarian Cancer , 2021, Frontiers in Oncology.
[5] M. Koual,et al. What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery? , 2021, Gynecologic oncology.
[6] He Huang,et al. The impact of lymph node dissection on survival in patients with clinical early-stage ovarian cancer , 2021, Journal of gynecologic oncology.
[7] Shanshan Cheng,et al. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. , 2021, Biochimica et biophysica acta. Reviews on cancer.
[8] P. Widschwendter,et al. CT Scan in the Prediction of Lymph Node Involvement in Ovarian Cancer – a Retrospective Analysis of a Tertiary Gyneco-Oncological Unit , 2020, Geburtshilfe und Frauenheilkunde.
[9] J. Lang,et al. Survival Analysis of Lymph Node Resection in Ovarian Cancer: A Population-Based Study , 2020, Frontiers in Oncology.
[10] D. Matei,et al. Supplemental online content for : NCCN Guidelines ® Insights : Ovarian Cancer , Version 1 . 2019 , 2019 .
[11] D. Timmerman,et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] M. Gumus,et al. Association of lymphadenectomy and survival in epithelial ovarian cancer. , 2019, Current problems in cancer.
[13] Jae-Weon Kim,et al. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms , 2019, The New England journal of medicine.
[14] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[15] C. Holman,et al. Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancer. , 2018, Cancer epidemiology.
[16] Cyril Ferdynus,et al. Decision curve analysis: a technical note. , 2018, Annals of translational medicine.
[17] A. Jemal,et al. Ovarian cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.
[18] G. Bogani,et al. Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses. , 2017, Gynecologic oncology.
[19] S. Houshmand,et al. An update on the role of PET/CT and PET/MRI in ovarian cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[20] R. Zweemer,et al. Surgical lymph node assessment in mucinous ovarian carcinoma staging: a systematic review and meta‐analysis , 2017, BJOG : an international journal of obstetrics and gynaecology.
[21] Thomas A. Sellers,et al. Epidemiology of ovarian cancer: a review , 2017, Cancer biology & medicine.
[22] Jeong-Won Lee,et al. Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis. , 2016, Gynecologic oncology.
[23] P. Konstantinopoulos,et al. Prognostic implications of reproductive and lifestyle factors in ovarian cancer. , 2016, Gynecologic oncology.
[24] San-Gang Wu,et al. Risk factors for lymph node metastasis in ovarian cancer: Implications for systematic lymphadenectomy. , 2016, International journal of surgery.
[25] D. Wallwiener,et al. Relevance of pelvic and para-aortic node metastases in early-stage ovarian cancer. , 2014, Anticancer research.
[26] D. Fischerová,et al. Imaging techniques for the evaluation of ovarian cancer. , 2014, Best practice & research. Clinical obstetrics & gynaecology.
[27] G. Yildirim,et al. Can CA-125 Predict Lymph Node Metastasis in Epithelial Ovarian Cancers in Turkish Population? , 2014, Disease markers.
[28] Jaime Prat,et al. Staging classification for cancer of the ovary, fallopian tube, and peritoneum , 2014, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[29] B. van Calster,et al. PET/CT in the staging of patients with a pelvic mass suspicious for ovarian cancer. , 2013, Gynecologic oncology.
[30] B. Rosner,et al. Hormonal and Reproductive Risk Factors for Epithelial Ovarian Cancer by Tumor Aggressiveness , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[31] Figo Guidelines. Staging classification for cancer of the ovary, fallopian tube, and peritoneum☆ , 2013 .
[32] F. Raspagliesi,et al. Systematic Para-aortic and Pelvic Lymphadenectomy in Early Stage Epithelial Ovarian Cancer: A Prospective Study , 2012, Annals of Surgical Oncology.
[33] Zhao-xiang Gu,et al. Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a meta-analysis. , 2012, European journal of radiology.
[34] J. Prat. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features , 2012, Virchows Archiv.
[35] T. Van Gorp,et al. Lymph node metastasis in stages I and II ovarian cancer: a review. , 2011, Gynecologic oncology.
[36] W. Cliby,et al. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. , 2011, Gynecologic oncology.
[37] Ewout W Steyerberg,et al. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.
[38] H. Haller,et al. Frequency and Distribution of Lymph Node Metastases in Epithelial Ovarian Cancer: Significance of Serous Histology , 2010, International Journal of Gynecologic Cancer.
[39] C. Coens,et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. , 2010, Journal of the National Cancer Institute.
[40] A. Reuss,et al. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] H. Chung,et al. Significance of preoperative serum CA‐125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer , 2008, Acta obstetricia et gynecologica Scandinavica.
[42] M. Gultekin,et al. Metastatic lymph node number in epithelial ovarian carcinoma: does it have any clinical significance? , 2008, Gynecologic oncology.
[43] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[44] J. Magrina,et al. Pelvic and aortic lymph node metastasis in epithelial ovarian cancer. , 2007, Gynecologic oncology.
[45] P. Harter,et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer , 2006, International Journal of Gynecologic Cancer.
[46] W. Cliby,et al. Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer. , 2006, American journal of obstetrics and gynecology.
[47] M. Piver. Treatment of ovarian cancer at the crossroads: 50 years after single-agent melphalan chemotherapy. , 2006, Oncology.
[48] V. Torri,et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis , 2006, British Journal of Cancer.
[49] Y. Hirai,et al. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors. , 2005, Gynecologic oncology.
[50] R. Rouzier,et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. , 2003, Journal of the American College of Surgeons.
[51] M. Franchi,et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. , 2003, Journal of the National Cancer Institute.
[52] B J McNeil,et al. Staging of advanced ovarian cancer: comparison of imaging modalities--report from the Radiological Diagnostic Oncology Group. , 2000, Radiology.
[53] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.